ReviewSurgical neurology international2026
Cognitive impairment in idiopathic intracranial hypertension: A conceptual framework and therapeutic implications.
Review in Surgical neurology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cognitive impairment is an increasingly recognized but poorly understood manifestation of idiopathic intracranial hypertension (IIH). Although deficits in attention, executive functioning, memory, processing speed, and reaction time have been reported, the characteristics, trajectory, and underlying mechanisms of cognitive dysfunction remain incompletely defined. Interpretation of the literature is limited by heterogeneity in study design, variability in neurocognitive assessment methods, and the absence of standardized cognitive outcome measures. Consequently, cognitive morbidity is overlooked in clinical practice and is not incorporated into treatment decision-making, which remains centered around visual outcomes and papilledema. Methods: In this narrative review, we synthesize evidence from IIH studies and related disease models to examine the putative mechanisms underlying cognitive dysfunction and propose a conceptual framework for its pathogenesis. Results: Cognitive dysfunction in IIH may arise through interactions between elevated intracranial pressure, cerebral venous hypertension, symptom-related amplifiers including chronic headache, sleep disturbance, pulsatile tinnitus, and psychiatric comorbidity, and broader biological and socioeconomic modifiers influencing cognitive vulnerability and recovery. This framework integrates current evidence and identifies potential pathways linking IIH to cognitive impairment. Conclusion: Improved understanding of the cognitive effects of IIH may help improve recognition of cognitive dysfunction in clinical care. Recognition of cognition as a clinically meaningful and potentially treatment-responsive outcome may help inform future studies evaluating whether cognition has a role in treatment selection, particularly in patients without papilledema, in whom disease burden may currently be underestimated.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.